Cargando…
Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder caused by mutations in the Dmd gene. In addition to skeletal muscle wasting, DMD patients develop cardiomyopathy, which significantly contributes to mortality. Antisense oligonucleotides (AOs) are a promising DMD therapy, restoring...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355666/ https://www.ncbi.nlm.nih.gov/pubmed/25758104 http://dx.doi.org/10.1038/srep08986 |
_version_ | 1782360899216998400 |
---|---|
author | Betts, Corinne A. Saleh, Amer F. Carr, Carolyn A. Hammond, Suzan M. Coenen-Stass, Anna M. L. Godfrey, Caroline McClorey, Graham Varela, Miguel A. Roberts, Thomas C. Clarke, Kieran Gait, Michael J. Wood, Matthew J. A. |
author_facet | Betts, Corinne A. Saleh, Amer F. Carr, Carolyn A. Hammond, Suzan M. Coenen-Stass, Anna M. L. Godfrey, Caroline McClorey, Graham Varela, Miguel A. Roberts, Thomas C. Clarke, Kieran Gait, Michael J. Wood, Matthew J. A. |
author_sort | Betts, Corinne A. |
collection | PubMed |
description | Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder caused by mutations in the Dmd gene. In addition to skeletal muscle wasting, DMD patients develop cardiomyopathy, which significantly contributes to mortality. Antisense oligonucleotides (AOs) are a promising DMD therapy, restoring functional dystrophin protein by exon skipping. However, a major limitation with current AOs is the absence of dystrophin correction in heart. Pip peptide-AOs demonstrate high activity in cardiac muscle. To determine their therapeutic value, dystrophic mdx mice were subject to forced exercise to model the DMD cardiac phenotype. Repeated peptide-AO treatments resulted in high levels of cardiac dystrophin protein, which prevented the exercised induced progression of cardiomyopathy, normalising heart size as well as stabilising other cardiac parameters. Treated mice also exhibited significantly reduced cardiac fibrosis and improved sarcolemmal integrity. This work demonstrates that high levels of cardiac dystrophin restored by Pip peptide-AOs prevents further deterioration of cardiomyopathy and pathology following exercise in dystrophic DMD mice. |
format | Online Article Text |
id | pubmed-4355666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43556662015-03-17 Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice Betts, Corinne A. Saleh, Amer F. Carr, Carolyn A. Hammond, Suzan M. Coenen-Stass, Anna M. L. Godfrey, Caroline McClorey, Graham Varela, Miguel A. Roberts, Thomas C. Clarke, Kieran Gait, Michael J. Wood, Matthew J. A. Sci Rep Article Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder caused by mutations in the Dmd gene. In addition to skeletal muscle wasting, DMD patients develop cardiomyopathy, which significantly contributes to mortality. Antisense oligonucleotides (AOs) are a promising DMD therapy, restoring functional dystrophin protein by exon skipping. However, a major limitation with current AOs is the absence of dystrophin correction in heart. Pip peptide-AOs demonstrate high activity in cardiac muscle. To determine their therapeutic value, dystrophic mdx mice were subject to forced exercise to model the DMD cardiac phenotype. Repeated peptide-AO treatments resulted in high levels of cardiac dystrophin protein, which prevented the exercised induced progression of cardiomyopathy, normalising heart size as well as stabilising other cardiac parameters. Treated mice also exhibited significantly reduced cardiac fibrosis and improved sarcolemmal integrity. This work demonstrates that high levels of cardiac dystrophin restored by Pip peptide-AOs prevents further deterioration of cardiomyopathy and pathology following exercise in dystrophic DMD mice. Nature Publishing Group 2015-03-11 /pmc/articles/PMC4355666/ /pubmed/25758104 http://dx.doi.org/10.1038/srep08986 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Betts, Corinne A. Saleh, Amer F. Carr, Carolyn A. Hammond, Suzan M. Coenen-Stass, Anna M. L. Godfrey, Caroline McClorey, Graham Varela, Miguel A. Roberts, Thomas C. Clarke, Kieran Gait, Michael J. Wood, Matthew J. A. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
title | Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
title_full | Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
title_fullStr | Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
title_full_unstemmed | Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
title_short | Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
title_sort | prevention of exercised induced cardiomyopathy following pip-pmo treatment in dystrophic mdx mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355666/ https://www.ncbi.nlm.nih.gov/pubmed/25758104 http://dx.doi.org/10.1038/srep08986 |
work_keys_str_mv | AT bettscorinnea preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT salehamerf preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT carrcarolyna preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT hammondsuzanm preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT coenenstassannaml preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT godfreycaroline preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT mccloreygraham preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT varelamiguela preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT robertsthomasc preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT clarkekieran preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT gaitmichaelj preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice AT woodmatthewja preventionofexercisedinducedcardiomyopathyfollowingpippmotreatmentindystrophicmdxmice |